AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.

[1]  M. Minden,et al.  Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. , 2017, Blood advances.

[2]  Gary D Bader,et al.  Tracing the origins of relapse in acute myeloid leukaemia to stem cells , 2017, Nature.

[3]  P. García,et al.  Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome , 2017, Oncotarget.

[4]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[5]  M. Levis,et al.  Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. , 2017, Blood.

[6]  J. Byrd,et al.  Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia , 2017, British journal of haematology.

[7]  Qi Zhou,et al.  Aberrant splicing and drug resistance in AML , 2016, Journal of Hematology & Oncology.

[8]  C. Dinardo,et al.  Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. , 2016, Clinical lymphoma, myeloma & leukemia.

[9]  John M. Ashton,et al.  Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. , 2016, Cell stem cell.

[10]  Gary D Bader,et al.  miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells , 2016, Cancer cell.

[11]  M. Minden,et al.  Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7 , 2015 .

[12]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[13]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[15]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[16]  H. Kantarjian,et al.  Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. , 2009, Blood.

[17]  M. Minden,et al.  Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy , 2008, American journal of hematology.

[18]  M. Gobbi,et al.  Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. , 2002, Journal of experimental & clinical cancer research : CR.

[19]  F. Appelbaum,et al.  Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). , 2001, Experimental hematology.

[20]  R. Pieters,et al.  IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA , 1996, British journal of haematology.